Research & Literature

Molecular phenotypes of DCIS predict overall and invasive recurrence.

Williams KE, Barnes NLP, Cramer A, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2015; (26(5)):1019-1025 doi:10.1093/annonc/mdv062.

p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.

Lodillinsky C, Infante E, Guichard A, et al.

Oncogene 2016; (35(3)):344-57 doi:10.1038/onc.2015.87.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Lancet (London, England) 2015; (386(10001)):1341-1352 doi:10.1016/S0140-6736(15)61074-1.

Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.

Petrelli F, Viale G, Cabiddu M, Barni S

Breast cancer research and treatment 2015; (153(3)):477-91 doi:10.1007/s10549-015-3559-0.

When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data.

Walker AJ, West J, Card TR, et al.

Blood 2016; (127(7)):849-57; quiz 953 doi:10.1182/blood-2015-01-625582.

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Runowicz CD, Leach CR, Henry NL, et al.

CA: a cancer journal for clinicians 2016; (66(1)):43-73 doi:10.3322/caac.21319.

Interobserver Variability of Ki-67 Measurement in Breast Cancer.

Chung YR, Jang MH, Park SY, et al.

Journal of pathology and translational medicine 2016; (50(2)):129-37 doi:10.4132/jptm.2015.12.24.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Burstein HJ, Lacchetti C, Anderson H, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(14)):1689-701 doi:10.1200/JCO.2015.65.9573.

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

Regan MM, Francis PA, Pagani O, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(19)):2221-31 doi:10.1200/JCO.2015.64.3171.

Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review.

Speers C, Pierce LJ

JAMA oncology 2016; (2(8)):1075-82 doi:10.1001/jamaoncol.2015.5805.

Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.

Tang P, Tse GM

Archives of pathology & laboratory medicine 2016; (140(8)):806-14 doi:10.5858/arpa.2015-0133-RA.

Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.

Bao T, Basal C, Seluzicki C, et al.

Breast cancer research and treatment 2016; (159(2)):327-33 doi:10.1007/s10549-016-3939-0.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, et al.

The New England journal of medicine 2016; (375(8)):717-29 doi:10.1056/NEJMoa1602253.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

von Minckwitz G, Procter M, de Azambuja E, et al.

The New England journal of medicine 2017; (377(2)):122-131 doi:10.1056/NEJMoa1703643.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

Krop I, Ismaila N, Andre F, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(24)):2838-2847 doi:10.1200/JCO.2017.74.0472.

Metastatic gastric cancer from breast carcinoma: A report of 78 cases.

Xu L, Liang S, Yan N, et al.

Oncology letters 2017; (14(4)):4069-4077 doi:10.3892/ol.2017.6703.

Breast Cancer Survivorship: Patient Characteristics and Plans for High-Quality Care.

Loftus LS, Sokol GH, Laronga C

Southern medical journal 2017; (110(10)):673-677 doi:10.14423/SMJ.0000000000000701.

Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.

D'Aloisio AA, Nichols HB, Hodgson ME, et al.

BMC cancer 2017; (17(1)):692 doi:10.1186/s12885-017-3686-6.

Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.

Wang M, Chen H, Wu K, et al.

Breast (Edinburgh, Scotland) 2018; (37()):56-63 doi:10.1016/j.breast.2017.10.011.

Anatomy and Breast Cancer Staging: Is It Still Relevant?

Plichta JK, Campbell BM, Mittendorf EA, Hwang ES

Surgical oncology clinics of North America 2018; (27(1)):51-67 doi:10.1016/j.soc.2017.07.010.

Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?

Rosso KJ, Weiss A, Thompson AM

Surgical oncology clinics of North America 2018; (27(1)):69-80 doi:10.1016/j.soc.2017.08.002.

Retrospective evaluation of histopathological examinations in invasive ductal breast cancer of no special type: an analysis of 691 patients.

Badowska-Kozakiewicz AM, Liszcz A, Sobol M, Patera J

Archives of medical science : AMS 2017; (13(6)):1408-1415 doi:10.5114/aoms.2015.53964.

Evidence-based recommendations on care for breast cancer survivors for primary care providers: a review of evidence-based breast cancer guidelines.

Spronk I, Korevaar JC, Schellevis FG, et al.

BMJ open 2017; (7(12)):e015118 doi:10.1136/bmjopen-2016-015118.

Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.

Smith BD, Bellon JR, Blitzblau R, et al.

Practical radiation oncology 2018; (8(3)):145-152 doi:10.1016/j.prro.2018.01.012.

Invasive Lobular Carcinoma of the Breast with Extracellular Mucin: Case Report of a New Variant of Lobular Carcinoma of the Breast.

Boukhechba M, Kadiri H, El Khannoussi B

Case reports in pathology 2018; (2018()):5362951 doi:10.1155/2018/5362951.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, et al.

The New England journal of medicine 2018; (379(2)):111-121 doi:10.1056/NEJMoa1804710.

Physical Activity, Exercise and Breast Cancer - What Is the Evidence for Rehabilitation, Aftercare, and Survival? A Review.

Wirtz P, Baumann FT

Breast care (Basel, Switzerland) 2018; (13(2)):93-101 doi:10.1159/000488717.

Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions.

Kilgore LJ, Korentager SS, Hangge AN, et al.

Annals of surgical oncology 2018; (25(10)):2948-2952 doi:10.1245/s10434-018-6601-8.

Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.

Weiss A, King TA, Hunt KK, Mittendorf EA

The Surgical clinics of North America 2018; (98(4)):687-702 doi:10.1016/j.suc.2018.03.005.

Modeling Human Ductal Carcinoma In Situ in the Mouse.

Behbod F, Gomes AM, Machado HL

Journal of mammary gland biology and neoplasia 2018; (23(4)):269-278 doi:10.1007/s10911-018-9408-0.

Oncologic Emergencies: Recognition and Initial Management.

Higdon ML, Atkinson CJ, Lawrence KV

American family physician 2018; (97(11)):741-748.

Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Denlinger CS, Sanft T, Baker KS, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(10)):1216-1247 doi:10.6004/jnccn.2018.0078.

Breast imaging surveillance after curative treatment for primary non-metastasised breast cancer in non-high-risk women: a systematic review.

Swinnen J, Keupers M, Soens J, et al.

Insights into imaging 2018; (9(6)):961-970 doi:10.1007/s13244-018-0667-5.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.

Geyer CE, Tang G, Mamounas EP, et al.

NPJ breast cancer 2018; (4()):37 doi:10.1038/s41523-018-0090-6.

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

von Minckwitz G, Huang CS, Mano MS, et al.

The New England journal of medicine 2019; (380(7)):617-628 doi:10.1056/NEJMoa1814017.

Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage.

Koh J, Kim MJ

Korean journal of radiology 2019; (20(1)):69-82 doi:10.3348/kjr.2018.0231.

Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment.

Kwon AY, Park HY, Hyeon J, et al.

PloS one 2019; (14(2)):e0212309 doi:10.1371/journal.pone.0212309.

[Update of the German S3 breast cancer guideline : What is new for pathologists?]

Lebeau A, Denkert C, Sinn P, et al.

Der Pathologe 2019; (40(2)):185-198 doi:10.1007/s00292-019-0578-3.

Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.

Gordian-Arroyo AM, Zynger DL, Tozbikian GH

American journal of clinical pathology 2019; (152(1)):17-26 doi:10.1093/ajcp/aqz012.

Sexual Dysfunction in Breast Cancer Survivors: Is it Surgical Modality or Adjuvant Therapy?

Gandhi C, Butler E, Pesek S, et al.

American journal of clinical oncology 2019; (42(6)):500-506 doi:10.1097/COC.0000000000000552.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

Andre F, Ismaila N, Henry NL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(22)):1956-1964 doi:10.1200/JCO.19.00945.

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.

Henry NL, Somerfield MR, Abramson VG, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(22)):1965-1977 doi:10.1200/JCO.19.00948.

Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer.

Seow YH, Wong RX, Lim JHC, et al.

Journal of breast cancer 2019; (22(2)):260-273 doi:10.4048/jbc.2019.22.e16.

Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10-year retrospective study.

Oluogun WA, Adedokun KA, Oyenike MA, Adeyeba OA

International journal of health sciences 2019; (13(4)):3-9.

Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.

Manahan ER, Kuerer HM, Sebastian M, et al.

Annals of surgical oncology 2019; (26(10)):3025-3031 doi:10.1245/s10434-019-07549-8.

FERTILITY PRESERVATION IN YOUNG WOMEN WITH EARLY-STAGE BREAST CANCER.

Vuković P, Kasum M, Raguž J, et al.

Acta clinica Croatica 2019; (58(1)):147-156 doi:10.20471/acc.2019.58.01.19.

Controversies in locoregional management of breast cancer with low volume pN0(i+) and pN1mi nodal disease.

Dosani M, Truong PT

Expert review of anticancer therapy 2019; (19(9)):803-810 doi:10.1080/14737140.2019.1660165.

The prognostic significance of co-existence ductal carcinoma in situ in invasive ductal breast cancer: a large population-based study and a matched case-control analysis.

Chen H, Bai F, Wang M, et al.

Annals of translational medicine 2019; (7(18)):484 doi:10.21037/atm.2019.08.16.

Clinical Oncology Society of Australia position statement on cancer survivorship care.

Vardy JL, Chan RJ, Koczwara B, et al.

Australian journal of general practice 2019; (48(12)):833-836 doi:10.31128/AJGP-07-19-4999.

Survivors of primary breast cancer 5 years after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study.

Leinert E, Kreienberg R, Wöckel A, et al.

Archives of gynecology and obstetrics 2020; (301(3)):761-767 doi:10.1007/s00404-020-05437-1.

Invasive breast cancer: Current perspectives and emerging views.

Shea EKH, Koh VCY, Tan PH

Pathology international 2020; (70(5)):242-252 doi:10.1111/pin.12910.

Multidisciplinary team approach in breast cancer care: Benefits and challenges.

Blackwood O, Deb R

Indian journal of pathology & microbiology 2020; (63(Supplement)):S105-S112 doi:10.4103/IJPM.IJPM_885_19.

Breast cancer survivorship.

Moore HCF

Seminars in oncology 2020; (47(4)):222-228 doi:10.1053/j.seminoncol.2020.05.004.

Neoadjuvant treatment for HER2-positive breast cancer.

Takada M, Toi M

Chinese clinical oncology 2020; (9(3)):32 doi:10.21037/cco-20-123.

Consensus statement on tumour bed localization for radiation after oncoplastic breast surgery.

Tse T, Knowles S, Bélec J, et al.

Current oncology (Toronto, Ont.) 2020; (27(3)):e326-e331 doi:10.3747/co.27.5977.

Diagnostic workup of early-stage breast cancer: can we choose more wisely?

Aks R, Peleg Hasson S, Sivan A, et al.

Breast cancer research and treatment 2020; (183(3)):741-748 doi:10.1007/s10549-020-05813-0.

Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution.

Aldrees R, Gao X, Zhang K, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2021; (34(2)):291-299 doi:10.1038/s41379-020-00650-4.

Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.

D'Hondt C, Vanhoeij M, Van Moer E, et al.

Breast cancer research and treatment 2020; (184(2)):433-444 doi:10.1007/s10549-020-05858-1.

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

Johnston SRD, Harbeck N, Hegg R, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(34)):3987-3998 doi:10.1200/JCO.20.02514.

Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.

Wang YJ, Chan YN, Jheng YW, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021; (29(6)):2959-2971 doi:10.1007/s00520-020-05796-0.

Febrile Neutropenia: Decreasing Time to Antibiotic Administration in a Community Hospital Emergency Department.

Bruce SD

Clinical journal of oncology nursing 2021; (25(1)):23-26 doi:10.1188/21.CJON.23-26.

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

Korde LA, Somerfield MR, Carey LA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.

Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification.

Tsang JY, Tse GM

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2021; (34(6)):1062-1073 doi:10.1038/s41379-021-00736-7.

Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual, 8th Edition, and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging.

Teichgraeber DC, Guirguis MS, Whitman GJ

AJR. American journal of roentgenology 2021; (217(2)):278-290 doi:10.2214/AJR.20.25223.

Cutaneous Metastatic Breast Cancer Masked by Hidradenitis Suppurativa.

Cohen-Kurzrock RA, Riahi RR

Cureus 2021; (13(1)):e12862 doi:10.7759/cureus.12862.

Cancer related emergencies with the chief complaint of pain: Incidence, ED recognition, and quality of care.

Alsharawneh A, Hasan AA

International emergency nursing 2021; (56()):100981 doi:10.1016/j.ienj.2021.100981.

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

Piccart M, van 't Veer LJ, Poncet C, et al.

The Lancet. Oncology 2021; (22(4)):476-488 doi:10.1016/S1470-2045(21)00007-3.

Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.

Kantor O, Laws A, Pastorello RG, et al.

Annals of surgical oncology 2021; (28(12)):7347-7355 doi:10.1245/s10434-021-09951-7.

Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Tischkowitz M, Balmaña J, Foulkes WD, et al.

Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(8)):1416-1423 doi:10.1038/s41436-021-01151-8.

Oncoplastic breast surgery: A guide to good practice.

Gilmour A, Cutress R, Gandhi A, et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2021; (47(9)):2272-2285 doi:10.1016/j.ejso.2021.05.006.

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

Burstein HJ, Curigliano G, Thürlimann B, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2021; (32(10)):1216-1235 doi:10.1016/j.annonc.2021.06.023.

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.

Brackstone M, Baldassarre FG, Perera FE, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(27)):3056-3082 doi:10.1200/JCO.21.00934.

Diagnostic Criteria for Breast Cancer-Related Lymphedema of the Upper Extremity: The Need for Universal Agreement.

Kassamani YW, Brunelle CL, Gillespie TC, et al.

Annals of surgical oncology 2022; (29(2)):989-1002 doi:10.1245/s10434-021-10645-3.

Combined Complete Decongestive Therapy Reduces Volume and Improves Quality of Life and Functional Status in Patients With Breast Cancer-Related Lymphedema.

Borman P, Yaman A, Yasrebi S, et al.

Clinical breast cancer 2022; (22(3)):e270-e277 doi:10.1016/j.clbc.2021.08.005.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

Kalinsky K, Barlow WE, Gralow JR, et al.

The New England journal of medicine 2021; (385(25)):2336-2347 doi:10.1056/NEJMoa2108873.

Pleomorphic Appearance of Breast Cancer Cutaneous Metastases.

Cohen PR

Cureus 2021; (13(12)):e20301 doi:10.7759/cureus.20301.

A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention.

Ridner SH, Dietrich MS, Boyages J, et al.

Lymphatic research and biology 2022; (20(6)):618-628 doi:10.1089/lrb.2021.0084.

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.

Harbeck N

Breast (Edinburgh, Scotland) 2022; (62 Suppl 1()):S12-S16 doi:10.1016/j.breast.2022.01.006.

Special Histologic Type and Rare Breast Tumors - Diagnostic Review and Clinico-Pathological Implications.

Tan BY, Lim EH, Tan PH

Surgical pathology clinics 2022; (15(1)):29-55 doi:10.1016/j.path.2021.11.003.

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.

Venetis K, Crimini E, Sajjadi E, et al.

Frontiers in molecular biosciences 2022; (9()):834651 doi:10.3389/fmolb.2022.834651.

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.

Andre F, Ismaila N, Allison KH, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(16)):1816-1837 doi:10.1200/JCO.22.00069.

Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.

Tokura M, Nakayama J, Prieto-Vila M, et al.

Cancer research 2022; (82(18)):3236-3248 doi:10.1158/0008-5472.CAN-22-0090.

Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis.

Li ZY, Dong YL, Cao XZ, et al.

Menopause (New York, N.Y.) 2022; (29(9)):1093-1100 doi:10.1097/GME.0000000000002019.

Radiologic-pathologic correlation in breast cancer: do MRI biomarkers correlate with pathologic features and molecular subtypes?

Galati F, Rizzo V, Moffa G, et al.

European radiology experimental 2022; (6(1)):39 doi:10.1186/s41747-022-00289-7.

The clinical significance of HER2 expression in DCIS.

Akrida I, Mulita F

Medical oncology (Northwood, London, England) 2022; (40(1)):16 doi:10.1007/s12032-022-01876-9.

Diagnostically Challenging Subtypes of Invasive Lobular Carcinomas: How to Avoid Potential Diagnostic Pitfalls.

Koufopoulos N, Pateras IS, Gouloumis AR, et al.

Diagnostics (Basel, Switzerland) 2022; (12(11)) doi:10.3390/diagnostics12112658.

The Impact of Tumor Boards on Breast Cancer Care: Evidence from a Systematic Literature Review and Meta-Analysis.

Di Pilla A, Cozzolino MR, Mannocci A, et al.

International journal of environmental research and public health 2022; (19(22)) doi:10.3390/ijerph192214990.

An international unified approach to reporting and grading invasive breast cancer. An overview of the International Collaboration on Cancer Reporting (ICCR) initiative.

Ellis IO, Rakha EA, Tse GM, Tan PH

Histopathology 2023; (82(1)):189-197 doi:10.1111/his.14802.

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

Johnston SRD, Toi M, O'Shaughnessy J, et al.

The Lancet. Oncology 2023; (24(1)):77-90 doi:10.1016/S1470-2045(22)00694-5.

Exploring the Integrated Role of AKT2, CD44v6, And MT1-MMP as Predictors of Axillary Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type.

Rustamadji P, Wiyarta E, Bethania KA

Iranian journal of pathology 2022; (17(4)):480-490 doi:10.30699/IJP.2022.551244.2866.

Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines.

Shah C, Whitworth P, Valente S, et al.

Breast cancer research and treatment 2023; (198(1)):1-9 doi:10.1007/s10549-022-06850-7.

How I treat HER2-low advanced breast cancer.

Schlam I, Tolaney SM, Tarantino P

Breast (Edinburgh, Scotland) 2023; (67()):116-123 doi:10.1016/j.breast.2023.01.005.

Regularly scheduled physical examinations and the detection of breast cancer recurrences.

Beltran-Bless AA, Alshamsan B, Alzahrani MJ, et al.

Breast (Edinburgh, Scotland) 2023; (69()):274-280 doi:10.1016/j.breast.2023.03.004.

Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.

Faragalla H, Plotkin A, Barnes P, et al.

Current oncology (Toronto, Ont.) 2023; (30(3)):3079-3090 doi:10.3390/curroncol30030233.

Does neoadjuvant chemotherapy provide any benefit for surgical de-escalation in luminal B, HER2(-) breast cancers?

Aktas A, Gunay-Gurleyik M, Aker F, et al.

Cirugia y cirujanos 2023; (91(2)):186-194 doi:10.24875/CIRU.22000277.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.

Wolff AC, Somerfield MR, Dowsett M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(22)):3867-3872 doi:10.1200/JCO.22.02864.

[Updated CAP guidelines for determining molecular biological subtypes of breast cancer].

Zavalishina LE, Oliushina EM, Andreeva YY, et al.

Arkhiv patologii 2023; (85(4)):39-46 doi:10.17116/patol20238504139.

Acute Oncologic Complications: Clinical-Therapeutic Management in Critical Care and Emergency Departments.

Gri N, Longhitano Y, Zanza C, et al.

Current oncology (Toronto, Ont.) 2023; (30(8)):7315-7334 doi:10.3390/curroncol30080531.

Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.

Mohamed A, Kruse M, Tran J

Expert review of anticancer therapy 2023; (23(10)):1071-1084 doi:10.1080/14737140.2023.2262764.

Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.

Ivanova M, Porta FM, D'Ercole M, et al.

Virchows Archiv : an international journal of pathology 2024; (484(1)):3-14 doi:10.1007/s00428-023-03656-w.

A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India.

Somal PK, Sancheti S, Sharma A, et al.

South Asian journal of cancer 2023; (12(2)):104-111 doi:10.1055/s-0043-1761942.

Effectiveness of manual lymphatic drainage in intensive phase I therapy of breast cancer-related lymphedema-a retrospective analysis.

Kasseroller RG, Brenner E

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2023; (32(1)):5 doi:10.1007/s00520-023-08210-7.

Locoregional Therapy: From Mastectomy to Reconstruction, Targeted Surgery, and Ultra-Hypofractionated Radiotherapy.

Banys-Paluchowski M, Hartmann S, Ditsch N, et al.

Breast care (Basel, Switzerland) 2023; (18(6)):428-439 doi:10.1159/000533748.

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.

Bedrosian I, Somerfield MR, Achatz MI, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(5)):584-604 doi:10.1200/JCO.23.02225.

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study.

Mannu GS, Wang Z, Dodwell D, et al.

BMJ (Clinical research ed.) 2024; (384()):e075498 doi:10.1136/bmj-2023-075498.

PARP Inhibitors for Breast Cancer Treatment: A Review.

Morganti S, Marra A, De Angelis C, et al.

JAMA oncology 2024; (10(5)):658-670 doi:10.1001/jamaoncol.2023.7322.

Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.

Curigliano G, Dent R, Earle H, et al.

ESMO open 2024; (9(4)):102989 doi:10.1016/j.esmoop.2024.102989.

Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.

Apostolova C, Ferroum A, Alhassan B, et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2024; (50(6)):108324 doi:10.1016/j.ejso.2024.108324.

Evaluation and management of febrile neutropenia in patients with cancer.

Cossey J, Cote MCB

JAAPA : official journal of the American Academy of Physician Assistants 2024; (37(8)):16-20 doi:10.1097/01.JAA.0000000000000054.

Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.

Sparano JA, Crager M, Gray RJ, et al.

NEJM evidence 2024; (3(8)):EVIDoa2300267 doi:10.1056/EVIDoa2300267.

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Bardia A, Hu X, Dent R, et al.

The New England journal of medicine 2024; (391(22)):2110-2122 doi:10.1056/NEJMoa2407086.

Single Cell Expression Analysis of Ductal Carcinoma in Situ Identifies Complex Genotypic-Phenotypic Relationships Altering Epithelial Composition.

Qin X, Strand SH, Lee MR, et al.

bioRxiv : the preprint server for biology 2024; doi:10.1101/2023.10.10.561724.

Risk factors for second primary breast cancer by laterality, age, and race and ethnicity.

John EM, Koo J, Ingles SA, et al.

Journal of the National Cancer Institute 2025; (117(3)):436-449 doi:10.1093/jnci/djae254.

Comparison of the Structural, Cytological and Biomarker Expression in Carcinoma in situ and Invasive Components in Breast Carcinoma.

Naimi A, Mohaghegh N

Iranian journal of pathology 2024; (19(3)):318-325 doi:10.30699/IJP.2024.2025907.3285.

Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.

Cooper K, Nalbant G, Essat M, et al.

Breast cancer research and treatment 2025; (210(2)):229-247 doi:10.1007/s10549-024-07596-0.

Fertility Preservation in People With Cancer: ASCO Guideline Update.

Su HI, Lacchetti C, Letourneau J, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(12)):1488-1515 doi:10.1200/JCO-24-02782.

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.

Park KU, Somerfield MR, Anne N, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(14)):1720-1741 doi:10.1200/JCO-25-00099.

Novel Postneoadjuvant Prognostic Breast Cancer Staging System.

Winchester DJ, Singh L, Edge SB, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(17)):1948-1960 doi:10.1200/JCO-24-01739.

Incidence, Clinicopathologic Features, and Follow-Up Results of human epidermal growth factor receptor-2-Ultralow Breast Carcinoma.

Hu Y, Jones D, Zhao W, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2025; (38(8)):100783 doi:10.1016/j.modpat.2025.100783.

HER2-Low Breast Cancer-Current Knowledge and Future Directions.

Shaaban AM, Kaur T, Provenzano E

Medicina (Kaunas, Lithuania) 2025; (61(4)) doi:10.3390/medicina61040644.

Enhancing prediction of thrombosis associated with breast cancer using prechemotherapy hematologic and coagulation characteristics.

Bucciol R, Parente H, Tera Y, et al.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2025; (36(5)):221-227 doi:10.1097/MBC.0000000000001367.

Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center.

Pai S, Murthy SV

Indian journal of surgical oncology 2025; (16(2)):478-490 doi:10.1007/s13193-023-01773-1.

The Approach to Multidisciplinary Oncologic Breast Care.

Owens WR, Ding Y, Quirarte DM, et al.

Seminars in plastic surgery 2025; (39(2)):97-102 doi:10.1055/s-0045-1806808.

Matrix stiffness-induced IKBKE and MAPK8 signaling drives a phenotypic switch from DCIS to invasive breast cancer.

Yan F, Göransson S, Olofsson H, et al.

Cell communication and signaling : CCS 2025; (23(1)):269 doi:10.1186/s12964-025-02276-y.

Addressing the Needs of Breast Cancer Survivors.

Sarfraz H, Zahra FT, Joshi U, O'Connor T

Current oncology reports 2025; (27(8)):986-1001 doi:10.1007/s11912-025-01687-x.

Role of immunotherapy in early breast cancer: past, present, and future.

Britten K, Bardia A, McAndrew N

Targeted oncology 2025; (20(4)):615-625 doi:10.1007/s11523-025-01157-1.

Epidemiological and molecular profile of breast cancer: a retrospective study in Casablanca, Morocco.

Khadiri K, Khadrouf Z, Mellouki A, et al.

The Pan African medical journal 2025; (50()):105 doi:10.11604/pamj.2025.50.105.43868.

Rare Presentation of Metastatic Breast Cancer Involving the Peritoneal Cavity: Two Cases Arising From Stage 0/1 Disease.

Saurborn E, Adkins J, Mahmud W, et al.

Cureus 2025; (17(6)):e86236 doi:10.7759/cureus.86236.

Patterns and prognostic implications of distant metastasis in breast Cancer based on SEER population data.

Zhang M, Deng H, Hu R, et al.

Scientific reports 2025; (15(1)):26717 doi:10.1038/s41598-025-12883-x.

Management of Neutropenic Fever in Persons with Cancer.

Doyle-Lindrud S

The Nursing clinics of North America 2025; (60(3)):479-489 doi:10.1016/j.cnur.2024.09.004.

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning.

Burciu OM, Merce AG, Cerbu S, et al.

Medicina (Kaunas, Lithuania) 2025; (61(7)) doi:10.3390/medicina61071280.

Impact of Patient Navigation on Radiation Therapy Completion in Black Breast Cancer Patients: Early Phase I Trial Results From the Navigator-Assisted Hypofractionation (NAVAH) Program.

McClelland S, Burnette U, Onyewadume L, et al.

American journal of clinical oncology 2026; (49(3)):125-126 doi:10.1097/COC.0000000000001257.

International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories.

Rakha EA, Tan PH, Van Bockstal MR, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2026; (39(1)):100925 doi:10.1016/j.modpat.2025.100925.

Adherence to Multidisciplinary Tumor Board (MTB) Recommendations in Patients With Breast Cancer: The Results From Two Cancer Centers in Germany.

Kandemir EA, Adam R, Roeper J, et al.

Clinical breast cancer 2025; (26(1)):13-21 doi:10.1016/j.clbc.2025.10.010.

Chronic Pain in the Cancer Survivor.

Maloney J, Kraus M, Strand N, et al.

Current pain and headache reports 2025; (29(1)):114 doi:10.1007/s11916-025-01431-x.

HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers.

Bagegni NA, Giridhar KV, Stewart D

Cancers 2025; (17(24)) doi:10.3390/cancers17244021.

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Curigliano G, Marotti L, Barrios C, et al.

Breast (Edinburgh, Scotland) 2026; (85()):104682 doi:10.1016/j.breast.2025.104682.

Comparison of Fertility-Related Recommendations Across National Comprehensive Cancer Network, ASCO, Clinical Oncology Society of Australia, and European Society for Medical Oncology Guidelines for People With Cancer Comparing Fertility Recommendations for People With Cancer.

Bhinder JK, Peera M, Al-Khaifi M

JCO oncology practice 2026; OP2500545 doi:10.1200/OP-25-00545.

Effects of Early Preventive Interventions on Breast Cancer-Related Lymphedema: A Meta-Analysis and Systematic Review.

Wu Y, Zhou Z, Li J, et al.

Cancer nursing 2026; doi:10.1097/NCC.0000000000001557.

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy.

Peng X, Chang W

Frontiers in medicine 2026; (13()):1775724 doi:10.3389/fmed.2026.1775724.

Evaluating the Association of Ki-67 with Oncotype DX Recurrence Score in Early-Stage ER-Positive/HER2-Negative Breast Cancer.

Dragoumis D, Kapetsis G, Louis K, et al.

Cancers 2026; (18(11)) doi:10.3390/cancers18111731.

Orbital metastasis from breast carcinoma: structured literature review and report of four cases.

Kim C, Bergman M, Fu R, et al.

Frontiers in ophthalmology 2026; (6()):1749352 doi:10.3389/fopht.2026.1749352.

Synthesis of clinical practice guidelines and recommendations for breast cancer survivorship care: a systematic review.

Anbari AB, Anderson L, Graves R, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2026; (34(8)).

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Caswell-Jin JL, Somerfield MR, Khan MA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; 101200JCO2602034 doi:10.1200/JCO-26-02034.